Ernexa Therapeutics Inc. CORRESP, filed Nov 13, 2024: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Eterna Therapeutics Inc.
1035 Cambridge Street, Suite 18A
Cambridge, MA 02141
(212) 582-1199
November 13, 2024
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Daniel Crawford
| Re: | Eterna Therapeutics Inc. | |
| Registration Statement on Form S-1 | ||
| Filed November 5, 2024 | ||
| File No. 333-283003 |
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Eterna Therapeutics Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above (the “Registration Statement”) be accelerated so that it will become effective at 4:30 p.m., Eastern Time, on November 15, 2024, or as soon thereafter as possible.
Please notify Edwin Astudillo of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at 858.720.8953 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request and/or contact him with any questions.
| Regards, | ||
| ETERNA THERAPEUTICS INC. | ||
| By: | /s/ Sandra Gurrola | |
| Name: | Sandra Gurrola | |
| Title: | Senior Vice President, Finance | |